Abstract:Amyloidosis includes a group of diseases characterized by the extracellular deposition of various fibrillary proteins that can autoaggregate in a highly abnormal fibrillary conformation. The amyloid precursor protein of systemic light-chain (AL) amyloidosis is comprised of monoclonal light chains that are due to plasma cell dyscrasia. The clinical presentation of patients with AL amyloidosis varies from patient to patient. Current treatment strategies target the clone in order to decrease the production of the pathologic light chains. Recent advances in therapy have helped many patients with AL amyloidosis achieve hematologic and organ responses.AL amyloidosis is the most common type of systemic amyloidosis in China with increasing morbidity and a high mortality rate. The clinical presentation of AL amyloidosis is variable, and the median overall survival was found to be 36.3 months. The disease prognosis and risk stratification are linked to serialized measurement of cardiac biomarkers and free light chains. The treatment of AL amyloidosis is mainly based on chemotherapy and autologous hematopoietic stem cell transplantation (ASCT). The use of novel agents (thalidomide, lenalidomide, and bortezomib) alone and in combination with steroids and alkylating agents has shown efficacy and continues to be explored.AL amyloidosis is the most common type of systemic amyloidosis in China with increasing morbidity and a high mortality rate. The lack of prospective clinical trials using the current therapies is a challenge for evidence-based decision making concerning the treatment of AL amyloidosis.(1) AL amyloidosis is the most prevalent type of amyloidosis accounting for 65% of the amyloidosis-diagnosed patients in the UK and for 93% of the amyloidosis-diagnosed patients in China. The predisposition of men over women to develop AL amyloidosis might be higher in China than in Western countries (2:1 vs. 1.3:1). Both in the East and West, incidence increases with age. At the time of diagnosis, edema is twice as frequent and the proportion of renal involvement is higher in Chinese compared to Western patients. (2) Melphalan followed by ASCT is the current standard therapy but is restricted to eligible patients. The efficacy and safety of bortezomib combined with dexamethasone were proven in Western patients and recently confirmed in a Chinese cohort. Recent studies in China and the US indicate that bortezomib induction prior to ASCT increases the response rate. Thalidomide and lenalidomide have shown benefit, but toxicity and lack of clinical evidence exclude these agents from first-line therapy. The green tea extract epigallocatechin-3-gallate is under investigation as an inhibitor of AL amyloid formation and a compound that might dissolve amyloid.

Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis

Current and Emerging Immunotherapies for Systemic AL Amyloidosis

Immune Therapies in AL Amyloidosis—A Glimpse to the Future

Immunotherapy in AL Amyloidosis

Systemic AL amyloidosis: current approach and future direction

The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China

The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis

Role of Palliative Care in the Supportive Management of AL Amyloidosis—A Review

Updates on Diagnosis, Staging, and Management

Clinical characteristics and survival analysis of a large cohort of Light Chain amyloidosis: a single center real-world study

Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain

Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis

Systemic Light Chain Amyloidosis: the Hope for a Cure.

Amyloid-Directed Antibodies: Past, Present, and Future

Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects

A pharmacist's review of the treatment of systemic light chain amyloidosis

Treatment of Systemic Immunoglobulin Light Chain Amyloidosis

[Detection of Abnormal Plasma Cells in Bone Marrow Contributes to the Diagnosis of Primary Systemic Light Chain Amyloidosis-Review].

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis

Physicochemical Strategies for Inhibition of Amyloid Fibril Formation: an Overview of Recent Advances